Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Journal of the National Cancer Institute 2006. 98(23): 1694-1706.

Antoniou AC, Pharoah PPD, Narod S et al .Breast and ovarian cancer risks to carriers of the BRCA15382insC and 185delAG and BRCA26174 del IT mutations: a combined analysis of 22 population-based studies. J Med Genet 2005. Jul; 42(7): 602-3

Antoniou AC, Pharoah PPD, Smith P and Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004. 1-11.

Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. NEJM 1997. 336: 1401-08

Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomark Prevent 2001. 10:467-473.

What Jewish women should know about breast and ovarian cancer. How your heritage can influence your optimal health care. Dr Lesley Andrews. Hereditary Cancer Clinic. Institute of Oncology. Prince of Wales Hospital.


BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, Antoniou et al 2004) is a risk model for familial breast and ovarian cancer. It was developed using complex segregation analysis of breast and ovarian cancer based on a combination of families in the UK identified through population-based studies of breast cancer and, families with multiple affected individuals who had been screened for BRCA1 and BRCA2 mutations. The BOADICEA Web Application (BWA) version was used on-line, for review of FRA-BOC categories, with permission from The University of Cambridge.

*In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.